The goal of the Methods in Clinical Cancer Research Workshop is to enable fellow and junior faculty clinical researchers in all oncology subspecialties to successfully initiate, develop, and implement effective clinical trial designs of therapeutic interventions in the treatment of patients with cancer.
Accreditation Statement and CME Credit Designation
In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AMA Credit Designation Statement - Physicians
The American Society of Clinical Oncology designates this live activity for a maximum of 29.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Any questions related to CE may be directed to ASCO Staff at firstname.lastname@example.org.
Participants can log into the ASCO CE Portal (cmeportal.asco.org) to claim the CE credit reflecting the extent of their participation in the Vail Workshop. CE certificates will be available for downloading and printing immediately following submission.
Certificates of Attendance will be available upon request for attendees who need a record of their attendance at the session but do not require documentation for continuing education purposes. Please note that this certifıcate does not award any AMA PRA Category 1 CreditTM.
In a 2012 survey conducted by the American Medical Association, only 1.5% of US physicians considered research as their primary focus, further supported by the 2014 NIH Physician-Scientific Workforce Group report, which recommended that medical and research training be further integrated. To address these concerning trends, strategies that seemed to demonstrate success in building and sustaining the involvement early investigators in clinical and translational research included intensive training, mentorship and career development tools.
In looking at recruitment and retention of trainees, while there is much investment in financially supporting and infrastructure for dual degree (MD/PhD and DO/PhD) training programs, medical students, resident and fellows must seek out and gain outside research experience on their own, which may be a barrier to continuing in this career pathway. During the transition stage from training to independence in their own research, data shows that physician-scientist loses interest when “at the transition from NIH career development award (K) to R funding or when they fail to renew their first R award” due in part to lack of mentorship, guidance in career development, and support for grant writing.
At the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation, one of the issues discussed at the workshop was the challenges faced by clinical investigators, where “obstacles include[d] locating funding, responding to multiple review cycles, obtaining Institutional Review Board (IRB) approvals, establishing clinical trial and material transfer agreements with sponsors and medical centers, recruiting patients, administering complicated informed consent agreements, securing protected research time from medical school departments, and completing large amounts of associated paperwork.” With additional education to provide strategies to overcome the challenges, clinical investigators may be more likely to pursue clinical research in their career.
Since 1996, the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) have jointly sponsored the Methods in Clinical Cancer Research Workshop with a primary goal of introducing clinical fellows and junior faculty in any oncology subspecialty to the principles of good clinical trials, exposing early-career scientists to the full spectrum of challenges in clinical research, and developing a cadre of well-trained, experienced clinical researchers whose expertise that will foster better clinical trial design.
The Vail Workshop is designed for clinical fellows and junior faculty clinical researchers from all oncology subspecialties, including radiation and surgical oncology. Additionally, patient advocates may also benefit from participation in this Workshop.
Upon participation in this activity, attendees will be able to:
- Recognize the principles of good clinical trial design;
- Address identified challenges in clinical research and assess the role that clinical research can play in an medical, surgery or radiation oncology career;
- Employ recommended strategies that will foster better clinical trial design.
Workshop Directors Disclosure Index
Financial relationships reported by the Workshop Course Directors are provided below. All relationships are considered self-held and compensated unless otherwise noted. None of these relationships are relevant to the content of the Workshop.
Jyoti D. Patel, MD
- - Consulting or Advisory Role: Ariad; Abbvie
Meredith M. Regan, ScD
- - Consulting or Advisory Role: Merck, Ipsen
- - Research Funding: Veridex (Inst); OncoGenex (Inst); Pfizer (Inst); Ipsen (Inst); Novartis (Inst); Merck (Inst); Ferring (Inst); Celgene (Inst); AstraZeneca (Inst); Pierre Fabre (Inst)
Patricia M. LoRusso, DO
- - Leadership: Genentech/Roche; Alexion Pharmaceuticals; Novartis; Boehringer Ingelheim
- - Consulting or Advisory Role: Alexion Pharmaceuticals; Novartis; ARIAD; Genmab; Glenmark; Menarini
- - Speakers’ Bureau: Genentech
- - Research Funding: Alexion Pharmaceuticals; Pfizer; Boehringer Ingelheim; Genentech (Inst); Novartis (Inst); Merrimack (Inst); Immunogen (Inst); Tensha Therapeutics (Inst); Taiho Pharmaceutical (Inst);
- - Travel, Accommodations, Expenses: Genentech/Roche; Alexion Pharmaceuticals
- - Honoraria: Genentech/Roche
Supported by the National Cancer Institute of the National Institutes of Health under Award Number R25CA068647. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
This activity is supported by educational grants from AbbVie, Inc., Amgen, Astellas, Celgene Corporation, Lilly, and Pfizer.
Educational Grant provided by: